Search Results - "Smith, Sheila Weiss"

Novel Adverse Events of Bevacizumab in the US FDA Adverse Event Reporting System Database: A Disproportionality Analysis by Shamloo, Behrooz K., Chhabra, Pankdeep, Freedman, Andrew N., Potosky, Arnold, Malin, Jennifer, Smith, Sheila Weiss

“…Background: Bevacizumab is the first in its class, vascular endothelial growth factor (VEGF) inhibitor that was initially approved by the US FDA in 2004 for…”
Get full text

Cancer Pharmacogenomics and Pharmacoepidemiology: Setting a Research Agenda to Accelerate Translation by Freedman, Andrew N., Sansbury, Leah B., Figg, William D., Potosky, Arnold L., Weiss Smith, Sheila R., Khoury, Muin J., Nelson, Stefanie A., Weinshilboum, Richard M., Ratain, Mark J., McLeod, Howard L., Epstein, Robert S., Ginsburg, Geoffrey S., Schilsky, Richard L., Liu, Geoffrey, Flockhart, David A., Ulrich, Cornelia M., Davis, Robert L., Lesko, Lawrence J., Zineh, Issam, Randhawa, Gurvaneet, Ambrosone, Christine B., Relling, Mary V., Rothman, Nat, Xie, Heng, Spitz, Margaret R., Ballard-Barbash, Rachel, Doroshow, James H., Minasian, Lori M.

“…Recent advances in genomic research have demonstrated a substantial role for genomic factors in predicting response to cancer therapies. Researchers in the…”
Get full text

Erythropoiesis-stimulating agents are not associated with increased risk of thrombosis in patients with myelodysplastic syndromes by SMITH, Sheila Weiss, SATO, Masayo, GORE, Steven D, BAER, Maria R, XUEHUA KE, MCNALLY, Diane, DAVIDOFF, Amy

“…There are limited reports of thrombosis among myelodysplastic syndrome patients exposed to erythropoiesis stimulating agents. It is not clear whether…”
Get full text

Impact of an Antimicrobial Allergy Label in the Medical Record on Clinical Outcomes in Hospitalized Patients by Charneski, Lisa, Deshpande, Gaurav, Smith, Sheila Weiss

“…Study Objective. To determine the impact of having an antimicrobial allergy label in the medical record on clinical outcomes in hospitalized patients. Design…”
Get full text

Patient and physician characteristics associated with erythropoiesis-stimulating agent use in patients with myelodysplastic syndromes by DAVIDOFF, Amy J, SMITH, Sheila Weiss, BAER, Maria R, XUEHUA KE, BIERENBAUM, Jason M, HENDRICK, Franklin, MCNALLY, Diane L, GORE, Steven D

“…Patient and physician characteristics associated with use of erythropoiesis-stimulating agents in myelodysplastic syndrome patients have not yet been…”
Get full text

Gastroenterologists' prescribing of infliximab for Crohn's disease: A national survey by St. Charles, Meaghan, Weiss Smith, Sheila R., Beardsley, Robert, Fedder, Donald O., Carter‐Pokras, Olivia, Cross, Raymond K.

“…Background: Practice guidelines suggest that immunomodulators (IMs) be given prior to infliximab (IFX) in patients with Crohn's disease (CD). The package…”
Get full text

Data Mining in Drug Safety: Review of Published Threshold Criteria for Defining Signals of Disproportionate Reporting by Deshpande, Gaurav, Gogolak, Victor, Smith, Sheila Weiss

“…Data mining is used in pharmacovigilance as an adjunct to traditional pharmacovigilance practices. There remains ongoing debate as to the impact automated…”
Get full text

Treatment and outcomes for chronic myelomonocytic leukemia compared to myelodysplastic syndromes in older adults by Zandberg, Dan P, Huang, Ting-Ying, Ke, Xuehua, Baer, Maria R, Gore, Steven D, Smith, Sheila Weiss, Davidoff, Amy J

“…Prior studies have investigated patients' characteristics, treatments, and outcomes for older adults with myelodysplastic syndromes, but most failed to…”
Get full text

Impact of an Electronic Medication Error Reporting System in a Hospice Organization (749) by Kim, Mina, Pharm.D, McPherson, Mary Lynn, Pharm.D BCPS, Weiss Smith, Sheila, PhD, Kopochis, Elizabeth, RN MS

Get full text

Improving Medication Error Reporting in Hospice Care by Boyer, Rachel, McPherson, Mary Lynn, Deshpande, Guarav, Weiss Smith, Sheila

“…The aims of this study are to determine the incidence of medication errors, characterize the type/severity of errors, and estimate the impact of an educational…”
Get full text

Blood pressure and bone mineral density in premenopausal and postmenopausal women by Kaplan, Sigal, Smith, Sheila R Weiss, Zuckerman, Ilene H

“…Previous studies regarding the associations between blood pressure (BP) and bone mineral density (BMD) have shown conflicting results. However, menopausal…”
Get more information

Sidelining Safety — The FDA's Inadequate Response to the IOM by Smith, Sheila Weiss

“…In a 2006 report, the Institute of Medicine implored the FDA to “embrace a culture of safety” by increasing the priority accorded to the safety of patients…”
Get full text

Association between diabetes patients' knowledge about medications and their blood glucose control by McPherson, Mary Lynn, Smith, Sheila Weiss, Powers, Atsuko, Zuckerman, Ilene H.

“…Diabetes mellitus is a common chronic disorder frequently resulting in hyperglycemia and numerous long-term complications. Research has shown that improved…”
Get full text

Did FDA safety warnings and CMS coverage restrictions improve guideline adherence for ESA use for patients with myelodysplastic syndromes? by Hendrick, Franklin, Baer, Maria R., Gore, Steven, Weiss Smith, Sheila, Davidoff, Amy J.

“…Abstract only e16519 Background: ESAs are used to treat anemia associated with MDS as an off-label indication. Our prior research demonstrated poor adherence…”
Get full text

Novel Adverse Events of Bevacizumab in the US FDA Adverse Event Reporting System Database by Shamloo, Behrooz K, Chhabra, Pankdeep, Freedman, Andrew N, Potosky, Arnold, Malin, Jennifer, Weiss Smith, Sheila

“…Background: Bevacizumab is the first in its class, vascular endothelial growth factor (VEGF) inhibitor that was initially approved by the US FDA in 2004 for…”
Get full text

A review of safety, efficacy, and utilization of erythropoietin, darbepoetin, and peginesatide for patients with cancer or chronic kidney disease: a report from the Southern Network on Adverse Reactions (SONAR) by Bennett, Charles L, Spiegel, David M, Macdougall, Iain C, Norris, LeAnn, Qureshi, Zaina P, Sartor, Oliver, Lai, Stephen Y, Tallman, Martin S, Raisch, Dennis W, Smith, Sheila Weiss, Silver, Samuel, Murday, Alanna S, Armitage, James O, Goldsmith, David

“…The erythropoiesis-stimulating agents (ESAs) erythropoietin and darbepoetin prevent transfusions among chemotherapy-associated anemia patients. Clinical…”
Get more information

Chronic Myelomonocytic Leukemia Is Associated with More Frequent and More Rapid Progression to Acute Myeloid Leukemia and Shorter Survival Than Myelodysplastic Syndrome, but Is Less Frequently Treated: Analysis of Surveillance Epidemiology and End Results Data Linked to Medicare Enrollment Claims by Zandberg, Dan, Huang, Ting-Ying, Ke, Xuehua, Baer, Maria R., Gore, Steven D., Smith, Sheila Weiss, Davidoff, Amy J.

“…Abstract 2784 Chronic myelomonocytic leukemia (CMML) is a clonal stem cell disorder that displays features of both a myelodysplastic syndrome (MDS) and a…”
Get full text

The FDA and the IOM Report by Galson, Steven K

“…To the Editor: In her Perspective article on the response of the Food and Drug Administration (FDA) to a report by the Institute of Medicine (IOM) on the U.S…”
Get full text

Access to Care, Race and Education Are Key Determinants of Erythropoietin Stimulating Agent (ESA) Use In Myelodysplastic Syndromes (MDS) by Davidoff, Amy J., Smith, Sheila Weiss, Baer, Maria R, Ke, Xuehua, Bierenbaum, Jason M, Hendrick, Franklin, McNally, Diane L., Gore, Steven D.

“…Abstract 3815 ESAs are recommended by the National Comprehensive Cancer Network for low-risk MDS patients with symptomatic anemia who have low serum…”
Get full text

Data Mining in Drug Safety: Review of Published Threshold Criteria for Defining Signals of Disproportionate Reporting by Deshpande, Gaurav, Gogolak, Victor, Weiss Smith, Sheila

“…Data mining is used in pharmacovigilance as an adjunct to traditional pharmacovigilance practices. There remains ongoing debate as to the impact automated…”
Get full text